Streetbeat News

Regulatory

CSCI

COSCIENS Biopharma announced that initial analysis of their study results suggests a high false positive rate in comparator tests, affecting macimorelin's ability to meet the primary efficacy endpoint.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 11:33 am

CSCI

Trading for CSCI has been halted as of 7:25 a.m. ET due to pending news. This indicates that significant information regarding the company is expected to be released soon, which could impact its stock price.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 11:25 am

LZM

Lifezone Metals has started the risk insurance process with the U.S. Development Finance Corporation for its nickel project in Tanzania. This move is aimed at mitigating potential risks associated with the project.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 11:06 am

OKYO

OKYO Pharma has secured a US patent for OK-101, a novel drug candidate for treating dry eye disease. OK-101 is a lipid conjugated chemerin peptide agonist targeting the ChemR23 receptor on immune cells in the eye, aiming to address inflammatory responses.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 11:01 am

BSX

Boston Scientific has received the CE Mark for its ACURATE Prime Aortic Valve System, a new transcatheter aortic valve replacement technology. This addition enhances their structural heart portfolio.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 10:59 am

MRK

Merck has started a Phase 3 trial named Shorespan-007 for Bomedemstat, targeting essential thrombocythemia patients who have not previously received cytoreductive therapy.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 10:49 am

BYDDF

BYDDY

BYD, backed by Warren Buffett, partners with Huawei to integrate advanced autonomous driving systems into its off-road EVs. This move aims to boost sales of BYD's premium brands, despite potential regulatory challenges in the U.S.

Portfolio Pulse from Benzinga Neuro

August 27, 2024 | 9:54 am

KKR

KKR has received all necessary regulatory approvals for its voluntary public tender offer to acquire all outstanding shares of OHB SE.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 9:10 am

BTC-USD

Pavel Durov, founder of Telegram, has been arrested in France, allegedly orchestrated by the US, according to a Russian official. The UAE seeks urgent consular access for Durov, a UAE citizen. Durov faces serious charges, and his arrest has raised global concerns, especially given Telegram's role in Russian military communications.

Portfolio Pulse from Benzinga Neuro

August 27, 2024 | 8:08 am

ALPMY

Astellas has initiated a Phase 3 trial for fezolinetant, targeting vasomotor symptoms in women with hormone receptor-positive breast cancer undergoing adjuvant endocrine therapy. The study, named HIGHLIGHT 1™, aims to address moderate to severe symptoms in patients with stage 0-3 cancer.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 7:15 am